Last updated on November 2017

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (spinosad) for the Treatment of Scabies

---

Brief description of study

Clinical research study for the treatment of scabies.

Detailed Study Description

The main purpose of this study is to compare the safety, efficacy, and tolerability of a once-daily topical application of IDP-123 Lotion compared to the IDP-123 Vehicle Lotion in subjects with moderate to severe acne. Subjects must be at least 9 years of age or older and generally healthy. IDP-123 is a lotion containing 0.045% tazarotene for the topical treatment of acne. “Vehicle” is a term to describe a lotion that does not contain any active drug (similar to a placebo). If you decide to be in this research study, you may receive either the IDP-123 Lotion or the IDP-123 Vehicle Lotion. IDP-123 Lotion is called an investigational drug because it has not been approved for sale by the United States Food and Drug Administration (FDA). Because this is a research study, the topical study drug, IDP-123 Lotion, will be given to you only during this study and not after the study is over. 

Assignment to IDP-123 Lotion or IDP-123 Vehicle Lotion will be done randomly, by chance (like tossing a coin). You will have a 50% (1 out of 2) chance of receiving active study lotion and a 50% (1 out of 2) chance of receiving Vehicle Lotion. For this study, all study drug applications will be on the face. 

Participation will be approximately 28 days( including 3 in office visits)

You may receive up to $150.00 if you complete the whole study, as a compensation for your time and travel.